Ajay K. Nooka, MD, MPH, FACP

The faculty discuss how CAR T-cell therapy, bispecific antibodies, and an antibody-drug conjugate differ in infection management and in how often patients need to be seen. They review the restricted access program and the eye exam before dosing, and a short segment covers working with an optometrist or ophthalmologist, and how brief the exam and form are. The panel then looks ahead to dosing schedule evolution, earlier-line use, and patient convenience. The panel closes with key takeaways on the head-to-head DREAMM-7 results, ocular monitoring, differences between the trial and the label, and room for different options in practice depending on the patient.

The program concludes with panelists discussing what would improve deliverability of the regimen in the community.

The faculty consider how to apply belantamab mafodotin in community practice, where clinicians typically see fewer patients with myeloma and want clear guidance and quick decisions. They discuss the therapy options available to patients and how access and distance from an academic center may shape the choice. They note that antibody-drug conjugates are familiar from other cancers, such as solid tumors and lymphomas, and proceed to describe an approach of assessing response and eye side effects after the first doses and then delaying or spacing doses as needed if the patient is responding to treatment.

One panelist reassures a responding patient whose dose is held that benefit does not depend on every-3-week dosing and that the eye has the ability to heal on its own, noting that patients at longer intervals in the study maintained benefit, some doing better by staying on treatment longer.

The moderator and the panelists then discuss how to prepare the patient for the first cycles.

The faculty turn to the safety and practical aspects of using belantamab mafodotin, drawing on earlier experience with the drug. They discuss how lines of therapy are defined and whether the definition needs refinement, and how efficacy endpoints translate into clinical relevance. Health-related quality of life is reviewed, with the view that good disease control is a driver of better quality of life. The panel describes holding the drug for eye symptoms, restarting at a lower dose, and adjusting dosing frequency to keep responding patients on therapy. They also note the overall response rate and MRD negativity in the study and discuss their interpretation of the data.

The moderator asks whether any of the patient’s baseline comorbidities from the clinical scenario in the previous episode are a concern.

One panelist addresses neuropathy in a patient who has received bortezomib, describing a symptom-driven approach.

The faculty discuss the DREAMM-7 eligibility and exclusion criteria, including the exclusion of patients refractory to daratumumab or bortezomib. They consider how well the trial population reflects patients seen in practice, given limited prior anti-CD38 exposure. The conversation then turns to the enrolled population vs the approved indication of at least 2 prior lines, which was based on a subgroup. Finally, the faculty share their views on that restriction and discuss the survival benefit seen in the study.

Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab dosing intervals to improve safety.

Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye toxicity with dose holds, and educate patients for confident dosing.

DREAMM-7 reveals belantamab combo extends myeloma PFS, with reversible eye effects, REMS monitoring, and fewer severe infections.

Experts explain who benefits from belantamab in relapsed myeloma and how REMS eye exams and dose tweaks keep treatment on track.

The faculty describe the approval of belantamab mafodotin with bortezomib and dexamethasone for patients who have had at least 2 prior lines of treatment including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), noting the boxed warning for ocular adverse effects.

The hosts open the program and set out what the discussion will cover in relapsed or refractory multiple myeloma: the area of unmet need in patients who have already received a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), the regulatory path that led from monotherapy to a combination, the DREAMM-7 trial design and efficacy outcomes, safety and monitoring, and where an antibody-drug conjugate (ADC) fits among the many options available at early relapse.

Ajay K. Nooka, MD, MPH, FACP, says multiple myeloma treatment is entering an immunotherapy deluge, with more data on bispecifics ahead.

Ajay K. Nooka, MD, MPH, FACP, says the teclistamab-talquetamab combination reduced progression risk by 89% in MonumenTAL-6.

The final segment synthesizes the discussion and looks ahead to the future of BCMA bispecifics. Jagannath recaps the extraordinary strides made thus far, from strong response rates to improved safety management, and highlights the growing role of combinations with agents like daratumumab and the expansion into newly diagnosed and smoldering myeloma clinical trials.

Here, the panel turns to one of the most debated questions surrounding bispecific antibodies: how long should patients remain on therapy? Jagannath raises a scenario involving a patient who achieves MRD-negative complete remission after 1 and 2 years of therapy, prompting discussion about whether to continue, taper, or discontinue treatment.

This segment tackles one of the most nuanced decisions in modern myeloma treatment: determining when to use BCMA CAR T-cell therapy versus a BCMA bispecific antibody.

This segment addresses one of the most rapidly evolving challenges in myeloma therapeutics: how to safely transition bispecific-treated patients between academic and community settings.

This segment focuses on the practical, multidisciplinary coordination required to safely administer bispecific antibodies.

Explore the complexities of treating a 72-year-old woman with relapsed refractory multiple myeloma using bispecific antibody therapy.

Explore the latest advancements in bispecific antibodies for treating BCMAs, highlighting their efficacy, administration frequency, and toxicity profiles.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Experts discuss the rapid advancements in BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma, highlighting improved response rates and treatment integration.

Panelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices to ensure equitable access to bispecific therapies, highlighting that it’s an exciting time in myeloma treatment with patient-friendly options that can be administered closer to home, and concluding that virtually no patient should be denied exposure to bispecific therapy before discontinuing treatment, while anticipating that de-escalated Q4 weekly schedules and trispecific agents will transform current practice patterns in the coming years.

Panelists discuss how a woman aged 69 years with standard-risk relapsed/refractory multiple myeloma (R/R MM), significant comorbidities including chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD), and history of respiratory infections would be a reasonable candidate for talquetamab despite infection concerns, citing that GPRC5D-targeting agents show much lower infection rates (less than 10%) compared with B-cell maturation antigen (BCMA) bispecifics (around 50%) due to preferential expression on malignant cells rather than normal B cells, with no requirement for prophylaxis and evidence of preserved humoral immunity including COVID-19 vaccine responses.

Panelists discuss how managing a high-risk patient aged 64 years who progressed after 11 months on talquetamab with decreased B-cell maturation antigen (BCMA) surface expression presents challenging options, including switching to GPRC5D-targeting agents like talquetamab, pursuing clinical trials, or potentially using sequential bispecifics despite T-cell exhaustion concerns, while noting that the MonumenTAL-1 trial’s prior BCMA-directed therapy cohort showed promising 12-month progression-free survival, although the data are confounded by intervening therapies between treatments.

Panelists discuss how despite the significant progress with bispecifics in relapsed/refractory multiple myeloma (R/R MM), major unanswered questions remain including optimal sequencing strategies (which represent the biggest challenge), how to implement bispecifics earlier in the treatment paradigm, and how to integrate them with other existing therapies in the evolving treatment landscape.